Cardiac Serum Marker Alterations After Intraoperative Radiotherapy with Low-energy X-rays in Early Breast Cancer As an Indicator of Possible Cardiac Toxicity

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2020 Aug 20

PMID 32813034

Citations 2

Authors

Stefan Stefanovic

Sebastian Berlit

Elena Sperk

Frederik Wenz

Christel Weiss

Frederik Trinkmann

Marc Sutterlin

Benjamin Tuschy

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess acute cardiac toxicity caused by intraoperative radiotherapy (IORT) with low-energy x‑rays for early breast cancer.

Methods: We prospectively analyzed pre- and postoperative troponin I and NT-proBNP in 94 women who underwent breast-conserving surgery between 2013 and 2017 at the Department of Gynecology and Obstetrics of the University Medical Center Mannheim, Germany. Thirty-nine women received IORT using low-energy x‑rays during breast-conserving surgery while 55 patients without IORT formed the control group. Demographic and surgical parameters as well as cardiac markers were evaluated.

Results: There were no significant differences concerning age and side of breast cancer between the groups. Furthermore, no significant difference between the troponin I assays of the IORT and control groups could be found (preoperatively: 0.017 ± 0.006 ng/ml vs. 0.018 ± 0.008 ng/ml; p = 0.5105; postoperatively: 0.019 ± 0.012 ng/ml vs. 0.018 ± 0.010 ng/ml; p = 0.6225). N‑terminal fragment of B‑type natriuretic peptide (NT-proBNP) was significantly higher in the control group 24 h after surgery (preoperatively: 158.154 ± 169.427 pg/ml vs. 162.109 ± 147.343 pg/ml; p = 0.56; postoperatively: 168.846 ± 160.227 pg/ml vs. 232.527 ± 188.957 pg/ml; p = 0.0279).

Conclusion: Troponin I levels as a marker of acute cardiac toxicity did not show any significant differences in patients who received IORT during breast-conserving surgery compared to those who did not.

Citing Articles

Major complications after intraoperative radiotherapy with low-energy x-rays in early breast cancer.

Berger L, Grimm A, Sutterlin M, Spaich S, Sperk E, Tuschy B Strahlenther Onkol. 2023; 200(4):276-286.

PMID: 37591980 PMC: 10965699. DOI: 10.1007/s00066-023-02128-z.

Role of Cardiac Biomarkers in Cancer Patients.

Semeraro G, Cipolla C, Cardinale D Cancers (Basel). 2021; 13(21).

PMID: 34771589 PMC: 8582425. DOI: 10.3390/cancers13215426.

References

Duma M, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R . Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO). Strahlenther Onkol. 2019; 195(10):861-871. DOI: 10.1007/s00066-019-01495-w. View

Eisenman A . Troponin assays for the diagnosis of myocardial infarction and acute coronary syndrome: where do we stand?. Expert Rev Cardiovasc Ther. 2006; 4(4):509-14. DOI: 10.1586/14779072.4.4.509. View

Tuschy B, Berlit S, Romero S, Sperk E, Wenz F, Kehl S . Clinical aspects of intraoperative radiotherapy in early breast cancer: short-term complications after IORT in women treated with low energy x-rays. Radiat Oncol. 2013; 8:95. PMC: 3643839. DOI: 10.1186/1748-717X-8-95. View

Neumaier C, Elena S, Grit W, Yasser A, Uta K, Anke K . TARGIT-E(lderly)--prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. BMC Cancer. 2012; 12:171. PMC: 3519765. DOI: 10.1186/1471-2407-12-171. View

DErrico M, Grimaldi L, Petruzzelli M, Gianicolo E, Tramacere F, Monetti A . N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2011; 82(2):e239-46. DOI: 10.1016/j.ijrobp.2011.03.058. View

Aziz M, Schneider F, Clausen S, Blank E, Herskind C, Afzal M . Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?. Radiat Oncol. 2011; 6:174. PMC: 3260102. DOI: 10.1186/1748-717X-6-174. View

Hardenbergh P, Munley M, Bentel G, Kedem R, Borges-Neto S, Hollis D . Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001; 49(4):1023-8. DOI: 10.1016/s0360-3016(00)01531-5. View

Vuolteenaho O, Ala-Kopsala M, Ruskoaho H . BNP as a biomarker in heart disease. Adv Clin Chem. 2005; 40:1-36. View

Vaidya J, Joseph D, Tobias J, Bulsara M, Wenz F, Saunders C . Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010; 376(9735):91-102. DOI: 10.1016/S0140-6736(10)60837-9. View

10.

Vaidya J, Wenz F, Bulsara M, Tobias J, Joseph D, Keshtgar M . Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2013; 383(9917):603-13. DOI: 10.1016/S0140-6736(13)61950-9. View

11.

Piroth M, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R . Heart toxicity from breast cancer radiotherapy : Current findings, assessment, and prevention. Strahlenther Onkol. 2018; 195(1):1-12. PMC: 6329735. DOI: 10.1007/s00066-018-1378-z. View

12.

Erven K, Florian A, Slagmolen P, Sweldens C, Jurcut R, Wildiers H . Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys. 2012; 85(5):1172-8. DOI: 10.1016/j.ijrobp.2012.09.022. View

13.

Abo-Madyan Y, Welzel G, Sperk E, Neumaier C, Keller A, Clausen S . Single-center long-term results from the randomized phase-3 TARGIT-A trial comparing intraoperative and whole-breast radiation therapy for early breast cancer. Strahlenther Onkol. 2019; 195(7):640-647. DOI: 10.1007/s00066-019-01438-5. View

14.

Darby S, Ewertz M, McGale P, Bennet A, Blom-Goldman U, Bronnum D . Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368(11):987-98. DOI: 10.1056/NEJMoa1209825. View

15.

Williams N, Pigott K, Brew-Graves C, Keshtgar M . Intraoperative radiotherapy for breast cancer. Gland Surg. 2014; 3(2):109-19. PMC: 4115764. DOI: 10.3978/j.issn.2227-684X.2014.03.03. View

16.

Cuzick J, Stewart H, RUTQVIST L, Houghton J, Edwards R, Redmond C . Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994; 12(3):447-53. DOI: 10.1200/JCO.1994.12.3.447. View

17.

Hughes-Davies L, Sacks D, Rescigno J, Howard S, Harris J . Serum cardiac troponin T levels during treatment of early-stage breast cancer. J Clin Oncol. 1995; 13(10):2582-4. DOI: 10.1200/JCO.1995.13.10.2582. View

18.

Wenz F, Welzel G, Blank E, Hermann B, Steil V, Sutterlin M . Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys. 2010; 77(5):1309-14. DOI: 10.1016/j.ijrobp.2009.06.085. View

19.

Jingu K, Nemoto K, Kaneta T, Oikawa M, Ogawa Y, Ariga H . Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys. 2007; 69(5):1417-23. DOI: 10.1016/j.ijrobp.2007.05.054. View

20.

Sedlmayer F, Reitsamer R, Wenz F, Sperk E, Fussl C, Kaiser J . Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol. 2017; 12(1):23. PMC: 5244574. DOI: 10.1186/s13014-016-0749-9. View